On Thursday, Shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), gained 0.80% to $0.0880.
AEterna Zentaris, declared that its lead oncology compound, zoptarelin doxorubicin (formerly AEZS‑108), met the primary end-point of the investigator-driven and sponsored Phase 2 clinical trial in Castration and taxane Resistant Prostate Cancer (CRPC) and demonstrated good tolerability. The primary endpoint was Clinical Benefit (CB) defined as remaining progression-free by RECIST and Prostate Specific Antigen (PSA) after treatment for 12+ weeks.
Results were presented this morning by lead investigator, Jacek Pinski , MD, PhD, of the USC Norris Comprehensive Cancer Center, during a poster session at the 18th ECCO – 40th ESMO European Cancer Congress in Vienna, Austria .
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health. The Company has three wholly owned direct and indirect auxiliaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned partner of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc.
Shares of Rambus Inc. (NASDAQ:RMBS), declined -0.42% to $11.75, during its last trading session.
Rambus, has been given an average recommendation of “Hold” by the seven research firms that are presently covering the company, AnalystRatingsNetwork.com reports. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $15.75.
Rambus Inc. is a technology solutions company. The Company’s technology portfolio addresses the evolving power, performance and security requirements of the mobile, cloud computing and connected device markets. It offers solutions in memory, chip interfaces and architectures, security and advanced light emitting diode (LED) lighting.
Shares of BP plc (ADR) (NYSE:BP), inclined 1.31% to $30.96, during its last trading session.
BMO Capital Markets began coverage on shares of BP plc (NYSE:BP) in a report issued on Monday morning, The Fly reports. The brokerage issued an outperform rating on the oil and gas exploration company’s stock.
The firm also revealed a dividend, which was paid on Friday, September 18th. Stockholders of record on Friday, August 7th were given a $0.60 dividend. The ex-dividend date of this dividend was Wednesday, August 5th.
BP p.l.c. (BP) is an integrated oil and gas company. The Company provides its customers with fuel for transportation, energy for heat and light, lubricants and the petrochemicals products used to make everyday items, counting paints, clothes and packaging.
Finally, PPL Corp (NYSE:PPL), ended its last trade with -0.88% loss, and closed at $32.60.
PPL Corporation, declared that William H. Spence, chairman, president and Chief Executive Officer presented to attendees at the Wolfe Research Power and Gas Leaders Conference in New York. Spence spoke at 1:30 p.m. on Wed., Sept. 30.
PPL Corporation (PPL) is an energy and utility holding company. Through its auxiliaries, PPL delivers electricity to customers in the United Kingdom, Pennsylvania, Kentucky, Virginia and Tennessee; delivers natural gas to customers in Kentucky; generates electricity from power plants in the northeastern, northwestern and southeastern United States, and markets wholesale or retail energy in the northeastern and northwestern parts of the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
